HulkaBSStarkAT. Breast cancer: cause and prevention. Lancet1995; 346:883–7.
3.
MantDVesseyMP. Epidemiology and primary prevention of breast cancer. In: BlandCopeland (eds) The breast. Comprehensive management of benign and malignant diseasesPhiladelphia:WB Saunders, 1991.
4.
MurphyMFGBroedersMJMCarpenterLM. Breast cancer risk in mothers of twins. Br J Cancer1997; 75:1066–8.
5.
KeyTJAWangDYBrownJB. A prospective study of urinary oestrogen excretion and breast cancer risk. Br J Cancer1996; 73:1615–9.
6.
HankinsonSEWillettWCMansonJE. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst1998; 90:1292–9.
7.
SmithOWSmithG van S. The influence of diethylstilboestrol on the progress and outcome of pregnancy as based on a comparison of treated with untreated primigravidas. Am J Obstet Gynecol1949; 58:994–1005.
8.
BrackbillYBerendesHW. Dangers of diethylstilboestrol: a review of a 1953 paper. Lancet1978; ii:520.
9.
HerbstALUlfelderHPoskanzerDC. Adenocarcinoma of the vagina. Association of maternal stilboestrol therapy with tumour appearance in young women. N Engl J Med1971; 284:878–81.
10.
HatchEEPalmerJRTitus-ErnstoffL. Cancer risk in women exposed to diethylstilbestrol in utero. JAMA1998; 280:630–4.
11.
ColtonTGreenbergRNollerK. Breast cancer in mothers prescribed diethylstilbestrol in pregnancy. JAMA1993; 269:2096–100.
12.
CalleEEMervisCAThunMJ. Diethylstilboestrol and risk of fatal breast cancer in a prospective cohort of US women. Am J Epidemiol1996; 144:645–52.
13.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet1996; 347:1713–27.
14.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception1996; 54(suppl):1S-106S.
15.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet1997; 350:1047–59.
16.
DiSaiaPJGrosenEAKurosakiT. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol1996; 174:1494–8.
17.
BeralVBanksEReevesGWallisM. Hormone replacement therapy and high incidence of breast cancer between mammographic screens. Lancet1997; 349:1103–4.
18.
HarveyJAPinkertonJVHermanCR. Short-term cessation of hormone replacement therapy and improvement of mammographic specifity. J Natl Cancer Inst1997; 89:1623–5.
19.
LayaMBLarsonEBTaplinSHWhiteE. Effect of estrogen replacement therapy on the specifity and sensitivity of screening mammography. J Natl Cancer Inst1996; 88:643–9.
